G6PD Deficiency Prevalence and Estimates of Affected Populations in Malaria Endemic Countries: A Geostatistical Model-Based Map

English version České info

Background:
Primaquine is a key drug for malaria elimination. In addition to being the only drug active against the dormant relapsing forms of Plasmodium vivax, primaquine is the sole effective treatment of infectious P. falciparum gametocytes, and may interrupt transmission and help contain the spread of artemisinin resistance. However, primaquine can trigger haemolysis in patients with a deficiency in glucose-6-phosphate dehydrogenase (G6PDd). Poor information is available about the distribution of individuals at risk of primaquine-induced haemolysis. We present a continuous evidence-based prevalence map of G6PDd and estimates of affected populations, together with a national index of relative haemolytic risk.

Methods and Findings:
Representative community surveys of phenotypic G6PDd prevalence were identified for 1,734 spatially unique sites. These surveys formed the evidence-base for a Bayesian geostatistical model adapted to the gene's X-linked inheritance, which predicted a G6PDd allele frequency map across malaria endemic countries (MECs) and generated population-weighted estimates of affected populations. Highest median prevalence (peaking at 32.5%) was predicted across sub-Saharan Africa and the Arabian Peninsula. Although G6PDd prevalence was generally lower across central and southeast Asia, rarely exceeding 20%, the majority of G6PDd individuals (67.5% median estimate) were from Asian countries. We estimated a G6PDd allele frequency of 8.0% (interquartile range: 7.4–8.8) across MECs, and 5.3% (4.4–6.7) within malaria-eliminating countries. The reliability of the map is contingent on the underlying data informing the model; population heterogeneity can only be represented by the available surveys, and important weaknesses exist in the map across data-sparse regions. Uncertainty metrics are used to quantify some aspects of these limitations in the map. Finally, we assembled a database of G6PDd variant occurrences to inform a national-level index of relative G6PDd haemolytic risk. Asian countries, where variants were most severe, had the highest relative risks from G6PDd.

Conclusions:
G6PDd is widespread and spatially heterogeneous across most MECs where primaquine would be valuable for malaria control and elimination. The maps and population estimates presented here reflect potential risk of primaquine-associated harm. In the absence of non-toxic alternatives to primaquine, these results represent additional evidence to help inform safe use of this valuable, yet dangerous, component of the malaria-elimination toolkit.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: G6PD Deficiency Prevalence and Estimates of Affected Populations in Malaria Endemic Countries: A Geostatistical Model-Based Map. PLoS Med 9(11): e32767. doi:10.1371/journal.pmed.1001339
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001339

Souhrn

Zdroje

1. FeachemRG, PhillipsAA, HwangJ, CotterC, WielgoszB, et al. (2010) Shrinking the malaria map: progress and prospects. Lancet 376: 1566–1578.

2. DasP, HortonR (2010) Malaria elimination: worthy, challenging, and just possible. Lancet 376: 1515–1517.

3. The Global Health Group and the Malaria Atlas Project (2011) Atlas of malaria-eliminating countries. San Francisco: The Global Health Group, Global Health Sciences, University of California, San Francisco.

4. MoonenB, CohenJM, SnowRW, SlutskerL, DrakeleyC, et al. (2010) Operational strategies to achieve and maintain malaria elimination. Lancet 376: 1592–1603.

5. CarltonJM, SinaBJ, AdamsJH (2011) Why is Plasmodium vivax a neglected tropical disease? PLoS Negl Trop Dis 5: e1160 doi:10.1371/journal.pntd.0001160

6. GoslingRD, OkellL, MoshaJ, ChandramohanD (2011) The role of antimalarial treatment in the elimination of malaria. Clin Microbiol Infect 17: 1617–1623.

7. KarlS, GurarieD, ZimmermanPA, KingCH, St PierreTG, et al. (2011) A sub-microscopic gametocyte reservoir can sustain malaria transmission. PLoS One 6: e20805 doi:10.1371/journal.pone.0020805

8. WellsTN, BurrowsJN, BairdJK (2010) Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol 26: 145–151.

9. WhiteNJ (2008) The role of anti-malarial drugs in eliminating malaria. Malar J 7Suppl 1: S8.

10. BairdJK, SchwartzE, HoffmanSL (2007) Prevention and treatment of vivax malaria. Curr Infect Dis Rep 9: 39–46.

11. BairdJK (2010) Eliminating malaria - all of them. Lancet 376: 1883–1885.

12. CappelliniMD, FiorelliG (2008) Glucose-6-phosphate dehydrogenase deficiency. Lancet 371: 64–74.

13. ShanksGD, KainKC, KeystoneJS (2001) Malaria chemoprophylaxis in the age of drug resistance. II. Drugs that may be available in the future. Clin Infect Dis 33: 381–385.

14. WHO (2010) Guidelines for the treatment of malaria, second edition. Geneva: World Health Organization.

15. WHO (2010) World malaria report 2010. Geneva: World Health Organization.

16. WHO (2011) Global plan for artemisinin resistance containment (GPARC). Geneva: World Health Organization.

17. SongJ, SocheatD, TanB, DaraP, DengC, et al. (2010) Rapid and effective malaria control in Cambodia through mass administration of artemisinin-piperaquine. Malar J 9: 57.

18. LawpoolsriS, KleinEY, SinghasivanonP, YimsamranS, ThanyavanichN, et al. (2009) Optimally timing primaquine treatment to reduce Plasmodium falciparum transmission in low endemicity Thai-Myanmar border populations. Malar J 8: 159.

19. GravesPM, GelbandH, GarnerP (2012) Primaquine for reducing Plasmodium falciparum transmission. Cochrane Database Syst Rev 9: CD008152.

20. ShekalagheSA, BousemaJT, KuneiKK, LushinoP, MasokotoA, et al. (2007) Submicroscopic Plasmodium falciparum gametocyte carriage is common in an area of low and seasonal transmission in Tanzania. Trop Med Int Health 12: 547–553.

21. Global Malaria Programme (2007) Malaria elimination: A field manual for low and moderate endemic countries. Geneva: World Health Organization.

22. The malERA Consultative Group on Diagnoses Diagnostics (2011) A research agenda for malaria eradication: diagnoses and diagnostics. PLoS Med 8: e1000396 doi:10.1371/journal.pmed.1000396

23. DouglasNM, NostenF, AshleyEA, PhaiphunL, van VugtM, et al. (2011) Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis 52: 612–620.

24. BairdJK, SurjadjajaC (2011) Consideration of ethics in primaquine therapy against malaria transmission. Trends Parasitol 27: 11–16.

25. Brueckner RP, Ohrt C, Baird JK, Milhous WK (2001) 8-Aminoquinolines. Rosenthal PJ, editor. Antimalarial chemotherapy: mechanisms of action, resistance, and new directions in drug discovery. Totowa (New Jersey): Humana Press.

26. BeutlerE (1994) G6PD deficiency. Blood 84: 3613–3636.

27. AbeyaratneKP, HalpeNL (1968) Sensitivity to primaquine in Ceylonese children due to deficiency of erythrocytic glucose-6-phosphate dehydrogenase. Ceylon Med J 13: 134–138.

28. BurgoineKL, BanconeG, NostenF (2010) The reality of using primaquine. Malar J 9: 376.

29. The malERA Consultative Group on Drugs (2011) A research agenda for malaria eradication: drugs. PLoS Med 8: e1000402 doi:10.1371/journal.pmed.1000402

30. APMEN Vivax working group. Annual Business and Technical meeting; 2011; Kota Kinabalu, Malaysia. Available: http://apmen.org/storage/apmen-iii/Dr%20Ric%20Price.pdf. Accessed 8 February 2012.

31. WHO Working Group (1989) Glucose-6-phosphate dehydrogenase deficiency. Bull World Health Organ 67: 601–611.

32. LuzzattoL, NotaroR (2001) Malaria. Protecting against bad air. Science 293: 442–443.

33. NkhomaET, PooleC, VannappagariV, HallSA, BeutlerE (2009) The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis 42: 267–278.

34. Cavalli-Sforza LL, Menozzi P, Piazza A (1994) The history and geography of human genes. Princeton (New Jersey): Princeton University Press. 1088 p.

35. PadillaCD, TherrellBL (2007) Newborn screening in the Asia Pacific region. J Inherit Metab Dis 30: 490–506.

36. SinghS (1973) Distribution of certain polymorphic traits in populations of the Indian peninsula and South Asia. Isr J Med Sci 9: 1225–1237.

37. Mourant AE, Kopec AC, Domaniewska-Sobczak K (1976) The distribution of the human blood groups and other polymorphisms. London: Oxford University Press.

38. Livingstone FB (1985) Frequencies of hemoglobin variants: thalassemia, the glucose-6-phosphate dehydrogenase deficiency, g6pd variants and ovalocytosis in human populations. New York: Oxford University Press.

39. GuerraCA, HaySI, LucioparedesLS, GikandiPW, TatemAJ, et al. (2007) Assembling a global database of malaria parasite prevalence for the Malaria Atlas Project. Malar J 6: 17.

40. HowesRE, PatilAP, PielFB, NyangiriOA, KabariaCW, et al. (2011) The global distribution of the Duffy blood group. Nat Commun 2: 266.

41. HaySI, GuerraCA, GethingPW, PatilAP, TatemAJ, et al. (2009) A world malaria map: Plasmodium falciparum endemicity in 2007. PLoS Med 6: e1000048 doi:10.1371/journal.pmed.1000048

42. Diggle PJ, Ribeiro PJ, Jr (2007) Model-based Geostatistics: Springer.

43. DiggleP, MoyeedR, RowlingsonB, ThomsonM (2002) Childhood malaria in the Gambia: a case-study in model-based geostatistics. J Roy Stat Soc C-App 51: 493–506.

44. ClementsAC, MoyeedR, BrookerS (2006) Bayesian geostatistical prediction of the intensity of infection with Schistosoma mansoni in East Africa. Parasitology 133: 711–719.

45. MagalhaesRJ, ClementsAC (2011) Mapping the risk of anaemia in preschool-age children: the contribution of malnutrition, malaria, and helminth infections in West Africa. PLoS Med 8: e1000438 doi:10.1371/journal.pmed.1000438

46. RasoG, MatthysB, N'GoranEK, TannerM, VounatsouP, et al. (2005) Spatial risk prediction and mapping of Schistosoma mansoni infections among schoolchildren living in western Cote d'Ivoire. Parasitology 131: 97–108.

47. PielFB, PatilAP, HowesRE, NyangiriOA, GethingPW, et al. Global estimates of sickle haemoglobin in newborns. Lancet Published online 25 Oct 2012. doi: http://dx.doi.org/10.1016/S0140-6736(12)61229-X.

48. PielFB, PatilAP, HowesRE, NyangiriOA, GethingPW, et al. (2010) Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nat Commun 1: 104.

49. HardyGH (1908) Mendelian proportions in a mixed population. Science 28: 49–50.

50. WeinbergW (1908) Über den nachweis der vererbung beim menschen. Jahreshefte des Vereins für vaterländische Naturkunde in Württemberg 64: 368–382.

51. PetersAL, Van NoordenCJ (2009) Glucose-6-phosphate dehydrogenase deficiency and malaria: cytochemical detection of heterozygous G6PD deficiency in women. J Histochem Cytochem 57: 1003–1011.

52. AbdulrazzaqYM, MicallefR, QureshiM, DawoduA, AhmedI, et al. (1999) Diversity in expression of glucose-6-phosphate dehydrogenase deficiency in females. Clin Genet 55: 13–19.

53. PatilAP, GethingPW, PielFB, HaySI (2011) Bayesian geostatistics in health cartography: the perspective of malaria. Trends Parasitol 27: 246–253.

54. BalkDL, DeichmannU, YetmanG, PozziF, HaySI, et al. (2006) Determining global population distribution: methods, applications and data. Adv Parasitol 62: 119–156.

55. United Nations Department of Economics and Social Affairs (2011) World population prospects, the 2010 Revision. New York: United Nationals Population Division.

56. YoshidaA, BeutlerE, MotulskyAG (1971) Human glucose-6-phosphate dehydrogenase variants. Bull World Health Organ 45: 243–253.

57. GethingPW, ElyazarIR, MoyesCL, SmithDL, BattleKE, et al. (2012) A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis 6: e1814 doi:10.1371/journal.pntd.0001814

58. GuindoA, FairhurstRM, DoumboOK, WellemsTE, DialloDA (2007) X-linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria. PLoS Med 4: e66 doi:10.1371/journal.pmed.0040066

59. RuwendeC, KhooSC, SnowRW, YatesSN, KwiatkowskiD, et al. (1995) Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. Nature 376: 246–249.

60. LeslieT, BricenoM, MayanI, MohammedN, KlinkenbergE, et al. (2010) The impact of phenotypic and genotypic G6PD deficiency on risk of Plasmodium vivax infection: a case-control study amongst Afghan refugees in Pakistan. PLoS Med 7: e1000283 doi:10.1371/journal.pmed.1000283

61. LouicharoenC, PatinE, PaulR, NuchprayoonI, WitoonpanichB, et al. (2009) Positively selected G6PD-Mahidol mutation reduces Plasmodium vivax density in Southeast Asians. Science 326: 1546–1549.

62. HedrickPW (2011) Population genetics of malaria resistance in humans. Heredity (Edinb) 107: 283–304.

63. LuzzattoL (2012) G6PD deficiency and malaria selection. Heredity (Edinb) 108: 456.

64. MinucciA, MoradkhaniK, HwangMJ, ZuppiC, GiardinaB, et al. (2012) Glucose-6-phosphate dehydrogenase (G6PD) mutations database: review of the “old” and update of the new mutations. Blood Cells Mol Dis 48: 154–165.

65. Luzzatto L (2009) Glucose-6-phosphate dehydrogenase deficiency. Orkin SH, Nathan DG, Ginsburg D, Look AT, Fisher DE, et al.., editors. Nathan and Oski's hematology of infancy and childhood. 7th ed. Philadelphia: Saunders.

66. BairdJK (2012) Chemotherapeutics challenges in developing effective treatments for the endemic malarias. Int J Parasitol In press.

67. BousemaT, DrakeleyC (2011) Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev 24: 377–410.

68. GuerraCA, HowesRE, PatilAP, GethingPW, Van BoeckelTP, et al. (2010) The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis 4: e774 doi:10.1371/journal.pntd.0000774

69. WHO (2011) Country antimalarial drug policies: by region. Geneva: WHO.

70. ClarkTG, FryAE, AuburnS, CampinoS, DiakiteM, et al. (2009) Allelic heterogeneity of G6PD deficiency in West Africa and severe malaria susceptibility. Eur J Hum Genet 17: 1080–1085.

71. DernRJ, BeutlerE, AlvingAS (1954) The hemolytic effect of primaquine. II. The natural course of the hemolytic anemia and the mechanism of its self-limited character. J Lab Clin Med 44: 171–176.

72. ShekalagheSA, ter BraakR, DaouM, KavisheR, van den BijllaardtW, et al. (2010) In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals. Antimicrob Agents Chemother 54: 1762–1768.

73. JohnsonMK, ClarkTD, Njama-MeyaD, RosenthalPJ, ParikhS (2009) Impact of the method of G6PD deficiency assessment on genetic association studies of malaria susceptibility. PLoS One 4: e7246 doi:10.1371/journal.pone.0007246

74. BairdJK (2009) Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev 22: 508–534.

75. DouglasNM, AnsteyNM, AngusBJ, NostenF, PriceRN (2010) Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 10: 405–416.

76. BairdJK (2011) Resistance to chloroquine unhinges vivax malaria therapeutics. Antimicrob Agents Chemother 55: 1827–1830.

77. BairdJK (2011) Radical cure: the case for anti-relapse therapy against all malarias. Clin Infect Dis 52: 621–623.

78. HarrisI, SharrockWW, BainLM, GrayKA, BobogareA, et al. (2010) A large proportion of asymptomatic Plasmodium infections with low and sub-microscopic parasite densities in the low transmission setting of Temotu Province, Solomon Islands: challenges for malaria diagnostics in an elimination setting. Malar J 9: 254.

79. WHO (2011) Consideration of mass drug administration for the containment of artemisinin resistant malaria in the greater Mekong subregion. Geneva: WHO.

80. KimS, NguonC, GuillardB, DuongS, ChyS, et al. (2011) Performance of the CareStart™ G6PD deficiency screening test, a point-of-care diagnostic for primaquine therapy screening. PLoS One 6: e28357 doi:10.1371/journal.pone.0028357

81. GethingPW, PatilAP, SmithDL, GuerraCA, ElyazarIR, et al. (2011) A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J 10: 378.